Comparative Pharmacology
Head-to-head clinical analysis: LO OVRAL 28 versus MODEYSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO OVRAL 28 versus MODEYSO.
LO/OVRAL-28 vs MODEYSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
400 mg orally once daily with food
None Documented
None Documented
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive